Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
300

Summary

Conditions
Depressive Disorder
Type
Observational
Design
Observational Model: Case-OnlyTime Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

The main objective is to assess neuroimaging biomarkers like cortical thickness predictive of poor outcome in major depressive disorder. Secondary objectives are : Identifying neuroimaging biomarker like Cerebral Blood Flow (CBF) predictive of poor outcome in major depressive disorder; Identifying m...

The main objective is to assess neuroimaging biomarkers like cortical thickness predictive of poor outcome in major depressive disorder. Secondary objectives are : Identifying neuroimaging biomarker like Cerebral Blood Flow (CBF) predictive of poor outcome in major depressive disorder; Identifying morphological biomarker like volumetric abnormalities (Voxel Based Morphometry - VBM), other than the cortical thickness, predictive of poor outcome in major depressive disorder; Identifying clinical features (sociodemographic, clinical dimensions such as apathy or anxiety) predictive of poor outcome of depression. This study expect to assess on a large population of patients: Clinical and neuroimaging markers (morphological and perfusion) predictive of poor outcome in major depressive disorder, allowing early identification of patients at risk of poor therapeutic response. These markers should allow a better stratification of patients; A better characterization of pathophysiological processes involved in major depressive disorder at different stages of the illness; Development of innovative technologies such as treatment with repetitive transcranial magnetic stimulation, or neurofeedback using real time fMRI, on both aspects of evaluation of the effectiveness and optimization of procedures. Such a study would open up on thinking in terms of therapeutic management. Indeed, recurrent and potentially resistant forms and screened using such predictive neuroimaging biomarkers could serve more specific therapeutic approaches in a preventive approach.

Tracking Information

NCT #
NCT02286024
Collaborators
Not Provided
Investigators
Principal Investigator: Dominique DRAPIER, MD Centre Hospitalier Guillaume Régnier, RENNES